In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease. Andrew Fein, managing director of equity research at H.C. Wainwright, said that “the worst case scenarios have largely been taken off the table,” noting better clarity following policy moves under Donald Trump. According to Dealogic data, IPO activity fell to 10 listings in 2025, the fewest in over a decade, down from 26 in 2024 and 93 in 2021, with proceeds decreasing to $1.6 billion from $16 billion in 2021.
Sentiment improved as equities gained momentum, with David Wagner claiming pricing trends became “more optimistic” in late 2025. Kevin Eisele, managing director at William Blair, said investors are more willing to deploy capital regardless of “headline risk.” Based on Seth Rubin, head of global equity capital markets at Stifel, markets will not return to their previous highs but will become “much more robust.”
With that said, here are the 8 Most Promising Biotech Stocks to Buy Now.
Vlad Teodor/Shutterstock.com
Methodology:
We used screeners to identify Biotech stocks with an average upside potential of at least 15%, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
On April 30, Oppenheimer raised its price target on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) from $104 to $111. It maintained an “Outperform” rating on the stock while noting shares rose after first-quarter results and updated guidance.
On April 29, Ionis Pharmaceuticals, Inc. reported first-quarter 2026 results. Growing demand for TRYNGOLZA is driven by launch execution while raising full-year revenue guidance.
The company said the FDA accepted the olezarsen sNDA for priority review, with launch preparations for severe hypertriglyceridemia progressing, while growing peak net sales guidance for TRYNGOLZA to over $3 billion.
The pipeline advanced. The firm said the FDA accepted the “zilganersen NDA” for priority review, positioning its first independent neurology launch.
CEO Brett Monia summed it up simply by stating that the business is performing well on both the commercial and R&D fronts. He noted future Phase 3 readouts and launches for olezarsen and zilganersen this year.
Ionis Pharmaceuticals, Inc. is a firm that develops and markets human therapeutic drugs using antisense technology. It is based in Carlsbad, California.
7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock.
On May 7, BridgeBio Pharma, Inc. posted first-quarter 2026 results, showing $194.5 million in total revenue. The revenue comprised of $180.6 million from U.S. Attruby net product sales, fueled by prescribing growth and patient persistence.
The company said demand grew across patient types, pointing out strong uptake among treatment-naive patients. It noted global traction following a Brazil approval.
BridgeBio Pharma, Inc. said real-world evidence showed Attruby reduced diuretic intensification by 43% versus tafamidis, citing an analysis released on medRxiv and an independent study presented at SCAI.
Pipeline activity continued, with the company stating it submitted an NDA for BBP-418 and plans filings for encaleret and infigratinib in 2026.
The firm reported $940.2 million in cash as of March 31 and authorized a $500 million share repurchase program.
BridgeBio Pharma, Inc. identifies and promotes novel medications to treat Mendelian diseases. Its development pipeline contains product candidates at various stages of development, from early discovery to late-stage development.
6. Summit Therapeutics Inc. (NASDAQ:SMMT)
On May 4, H.C. Wainwright reduced its price goal on Summit Therapeutics Inc. (NASDAQ:SMMT) to $23 from $30. The firm also noted a weaker interim signal from HARMONi-3 and flagged added risk to the final squamous readout expected in the 2026 second half.
On April 30, Summit Therapeutics Inc. released its first quarter 2026 results. More than 4000 individuals have received ivonescimab in clinical studies throughout the world. It has been used commercially by over 70000 patients in China through a partner, Akeso.
The business also mentioned that the independent monitoring committee recommended continuing the HARMONi-3 squamous cohort as planned. Final progression-free survival findings are expected in the 2026 second half, and no safety hazards were detected.
Summit Therapeutics Inc. had $598.7 million in cash on March 31, down from $713.4 million at the end of the year, while GAAP operating costs grew to $195.2 million from $66.8 million.
Summit Therapeutics Inc. is a biopharmaceutical firm. The company’s main product, Ridinilazole, is an orally given small molecule antibiotic now in Phase III clinical research to treat CDI.
5. Genmab A/S (NASDAQ:GMAB)
On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares.
On May 7, Genmab A/S reported revenue of $896 million for Q1 2026, rising 25% from $715 million a year earlier. The growth was because of higher DARZALEX and Kesimpta royalties and solid EPKINLY sales. Royalty income did the heavy lifting, soaring to $742 million from $589 million, as underlying drug sales expanded.
Costs climbed too, as Genmab A/S reported operating expenses of $606 million, growing by 25%, showing pipeline growth and marketing investments. Profit held steady, posting an operating profit of $180 million compared to $188 million last year, while adjusted operating profit reached $237 million, up from $191 million.
Jan van de Winkel said Genmab A/S made “tangible progress,” pushing late-stage programs and preparing for launches. It maintained 2026 guidance.
Genmab A/S is a global biotechnology company that works on the development of human antibody therapies for cancer and other diseases.
4. Insmed Incorporated (NASDAQ:INSM)
On May 7, Insmed Incorporated (NASDAQ:INSM) reported first-quarter 2026 financials. The company posted a total revenue of $306.0 million because of BRINSUPRI generating $207.9 million and ARIKAYCE contributing $98.1 million. BRINSUPRI revenue surged 44% sequentially from Q4 2025, while ARIKAYCE rose 6% YoY, showing international expansion.
Will Lewis, CEO, said in the release that commercial momentum and pipeline progress continued to build, spotlighting BRINSUPRI’s launch path and ENCORE data strength. Insmed Incorporated also stated that the study fulfilled its primary and all multiplicity-controlled secondary goals. It prepared ARIKAYCE for an SNDAs filing with the FDA in the second half of 2026.
Guidance remained solid. The company reiterated its forecasts for BRINSUPRI revenue of at least $1 billion in 2026 and ARIKAYCE sales of $450 million to $470 million. It also launched the Phase 3 PALM-PAH study of TPIP in April, adding to its late-stage pipeline.
Insmed Incorporated is a biopharmaceutical company that produces and markets medicines for rare diseases. It focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder pipelines.
3. BeOne Medicines AG (NASDAQ:ONC)
On May 8, Morgan Stanley raised its price target for BeOne Medicines AG (NASDAQ:ONC) from $389 to $395. It retained an “Overweight rating” on the shares.
On May 7, 2026, Morningstar reported that BeOne Medicines AG posted first-quarter GAAP net income of $227.4 million, surging from $1.3 million a year earlier. The revenue climbed by 35% because of strong flagship cancer drug sales expanding across the U.S. and Europe.
Profitability sharpened, posting adjusted EPS of $3.24, the company said.
Chief executive John V. Oyler said in the filing that earnings supported continued global growth, while Nomura analyst Jialin Zhang called the guidance raise “satisfactory,” backing a positive view, Dow Jones reported.
The company also recently landed a global licensing agreement with Chinese biotech firm Huahui Health worth up to $1.9 billion for exclusive rights to an oncology treatment. It joined a growing list of global biopharma companies looking to capitalize on China’s emerging pipeline of novel drugs.
BeOne Medicines AG is a global oncology company. It is based in Switzerland and concentrates on discovering and creating treatments that are cheaper and more accessible to cancer patients around the world.
2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock.
Alnylam Pharmaceuticals, Inc. reported first quarter 2026 financials, delivering global net product revenues of $1.036 billion, climbing 121% year over year. This was powered by total TTR revenues of $910 million that surged 153%. That momentum came largely from AMVUTTRA contributing $890 million, with ONPATTRO adding $20 million, together anchoring the TTR franchise.
M.D Chief Executive Officer of Alnylam, Yvonne Greenstreet, said in the company’s statement that the quarter marked “over $1 billion in quarterly product revenues for the first time.” She pointed to ongoing progress across Phase 3 and Phase 1 pipeline programs.
Alnylam Pharmaceuticals, Inc. reiterated its 2026 outlook, guiding for $4.9 billion to $5.3 billion in total net product revenues. It includes $4.4 billion to $4.7 billion from TTR products.
Alnylam Pharmaceuticals, Inc. develops and markets RNA interference-based therapeutics. The company is headquartered in Cambridge, MA.
1. argenx SE (NASDAQ:ARGX)
On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple seronegative patients.
On May 7, argenx SE reported first-quarter 2026 financials, posting $1.3 billion in global product net sales, up 63% year over year, while flagging a May 10, 2026, PDUFA date for seronegative gMG. CEO Karen Massey said argenx “continues to deliver meaningful impact,” citing a 17th consecutive quarter of VYVGART growth and pointing to expansion across MG populations.
Argenx said it expects myositis topline data in the third quarter and MMN readouts in the fourth quarter of 2026 while advancing FcRn programs, including Phase 3-ready ARGX-213. Management added that it aims to treat 50,000 patients globally and secure 10 labeled signs by 2030, the company said.
argenx SE is a global immunology company that works to improve the lives of people suffering from severe autoimmune diseases. It is operated in the United States, Japan, EMEA, and China.
READ NEXT: 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen and 8 Best European Industrial Stocks to Buy Now.
Hedge Fund Resource Center